Colorcon Opens Major Facility in India - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Colorcon Opens Major Facility in India

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5

Colorcon announced that it has completed a major expansion of its South Asia production facility in Verna, Goa, India. The Goa site operates under schedule M of the Indian FDA and IPEC guidelines, with Colorcon accredited to the latest ISO 9001 standard.

Colorcon provides film coatings, modified-release technologies, functional excipients and tablet-design services to the pharmaceutical industry. The Goa plant is one of six Colorcon manufacturing plants dedicated to film coatings. These plants are strategically located close to key customer centers in India, China, Europe, North America and Japan.

Subodh Priolkar, regional managing director for South Asia, said during the opening event that the investment would enable Colorcon to continue to meet the needs of its customers through security of supply and short lead times.

Martti Hedman, CEO of Colorcon, added that India is one of the fastest growing pharmaceutical markets and is also the most important production cluster of generic medicines for global markets. “Colorcon is investing heavily in India to support its customers during both development and manufacture,” Hedman said. “Speed to market, cost to produce and consistently high product quality are our customers’ strategic objectives.”

Source: Colorcon

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here